ERBB2 and breast cancer: HSP90 inhibitors such as 17‐AAG in combination with trastuzumab have shown the most promise in HER2+ breast cancer because HER2 is a known client protein of HSP90 (De Mattos‐Arruda and Cortes, 2012).